Akums Drugs and Pharmaceuticals Limited — Others, 06-02-2025: Statement of deviation(s) or variation(s) under Reg. 32

Akums Drugs & Pharmaceuticals has provided a statement confirming that there were no deviations or variations in the utilization of funds raised through its Initial Public Offer (IPO) for the quarter ended 31st December 2024. The IPO raised ₹680 crore, and the Audit Committee reviewed and approved this statement. The positive oversight by the Audit Committee reinforces management's operational efficacy, which can bolster investor confidence in the company’s financial discipline. This clarity may enhance investor sentiment, reflecting a strong governance framework while presenting a stable outlook for potential growth initiatives.